By Dr. David Vincent, VTI Life Sciences CSO/ B.Sc., MPH, PhD
Introduction
Each year, snakebite envenoming remains a substantial yet underrecognized global public health problem, disproportionately affecting rural and resource-constrained populations, particularly in sub-Saharan Africa, South Asia, Southeast Asia, and parts of Latin America. The burden is heaviest among agricultural workers, children, and communities with limited access to prompt medical care or effective antivenom therapy. According to the World Health Organization (2023), there are between 5.4 million snakebites annually, of which 1.8 to 2.7 million results in envenoming, causing 81,000 to 138,000 deaths each year. In addition to mortality, millions more suffer long-term effects, including amputations, permanent disability, chronic pain, and psychological trauma resulting from the tissue-destroying effects of venom or delayed treatment.
Despite its devastating impact, snakebite envenoming has long been neglected in global health agendas, often overshadowed by more prominent infectious diseases. However, renewed attention from the WHO, scientists, and nonprofit organizations has catalyzed a shift, positioning snakebite as a preventable and treatable condition within reach of current technologies and coordinated global action.
Monovalent vs. Polyvalent Antivenoms: The Current Landscape
Historically, many regions have relied on monovalent antivenoms, derived from immunizing animals, typically horses, with the venom of a single snake species. These products are highly specific and can be extremely effective if the offending species is correctly identified. In clinical contexts where one snake species predominates (e.g., Naja naja in parts of India), monovalents provide focused neutralization with a lower risk of adverse immune reactions (Chippaux, 2017).
However, the practical limitations of monovalents are clear in low-resource or rural settings, where snake identification is delayed or impossible. Victims often arrive at clinics without having seen the snake, or with a dead specimen that’s misidentified. Such scenarios increase the risk of administering ineffective treatment, prolonging suffering, or causing avoidable death (Williams et al., 2019).
In contrast, polyvalent antivenoms (pAVs) are formulated by immunizing host animals with venoms from multiple medically important species, resulting in antibodies that neutralize a broader array of toxins. These formulations improve real-world outcomes by removing the need for species-specific diagnosis (Leon et al., 2021).
A 2023 review by Ratanabanangkoon et al. emphasized that well-formulated polyvalents, especially those designed regionally offer superior practical benefits in high-biodiversity areas such as Sub-Saharan Africa, Southeast Asia, and Latin America. Still, some nations remain committed to monovalent due to regulatory inertia, legacy practices, or a false perception of cost efficiency.
Moreover, creating effective polyvalent products requires rigorous venom selection, given intra-species variability across geography, age, and diet. This complexity presents both scientific and logistical hurdles that demand local surveillance and adaptable manufacturing platforms.
Opportunities Through New Technologies and Innovation
Recent breakthroughs in biotechnology, protein engineering, and pharmaceutical manufacturing are creating promising alternatives to traditional snake “milking”—a process that has long formed the backbone of antivenom production but remains labor-intensive, ethically sensitive, and biologically variable. These innovations hold the potential to enhance the precision, scalability, safety, and cost-effectiveness of antivenom development while reducing reliance on high-risk manual venom extraction from live snakes.
Venom Proteomics and Toxin Component Analysis
Recent advances in technology could make traditional snake “milking” (venom collection), which is labor-intensive, logistically risky, and expensive, less central to the process, or at least make it more efficient. Some of the innovations and approaches include:
- Venom proteomics and toxin component analysis: Venom is a complex biochemical cocktail composed of enzymes, neurotoxins, cytotoxins, hemotoxins, and other bioactive peptides, many of which vary across snake species, geographic regions, and even individual animals. Advanced proteomic mapping techniques, such as mass spectrometry and high-throughput sequencing, now enable researchers to identify and quantify the most clinically relevant toxins within a species or regional venom profile.
- Recombinant toxin or synthetic analogues: Synthetic or recombinant versions of major toxin proteins may substitute for venom extraction, intensifying the immune stimulus without needing large numbers of venomous snakes.
- Monoclonal antibody fragments: Humanized or animal-human-human chimeric monoclonals that can neutralize venom components may eventually complement or replace the horse-based IgG series.
- Improved adjuvants and delivery regimens: better adjuvants, optimized schedules, and more efficient delivery methods can increase the breadth and speed of antibody production.
- Advanced manufacturing and stabilization: Lyophilization (freeze-drying), generation of F(ab’)₂ or Fab fragments, and thermostable diluent formulations improve shelf life in hot, rural regions.
By focusing immunization efforts on only the most lethal and immunodominant components, scientists can generate more potent and consistent immune responses in production animals, reduce unnecessary animal exposure, and minimize variability in antivenom efficacy. This data-driven approach forms the foundation for rational design
Case Studies and Regional Developments
Snakebite management varies widely across the world, reflecting differences in venomous species, healthcare infrastructure, and antivenom production capacity. Examining regional strategies provides valuable insight into both the challenges and successes that can guide future global approaches.
Australia
Australia maintains a dual approach: monovalents for well-defined threats and polyvalents in remote areas. Backed by rigorous diagnostic protocols, this hybrid strategy has yielded one of the lowest snakebite mortality rates globally (Australian Toxicology Network, 2023).
India and Sri Lanka
India’s “Big Four” polyvalent antivenom targets cobra, krait, viper, and saw-scaled viper. However, efficacy drops outside core regions. For example, eastern krait bites and Sri Lanka’s hump-nosed pit viper remain poorly treated. Region-specific recombinant solutions are under development (Sharma et al., 2022).
Africa
Africa faces fragmented supply chains, inconsistent product quality, and regulatory gaps. However, WHO’s Regional Office has launched a master plan emphasizing local production, affordability, and quality surveillance. Programs in Kenya, Nigeria, and Uganda are showing promise.
Institutional and Leadership Imperatives: A Role for New Champions
To reduce global mortality and morbidity from snakebite, technical solutions alone are insufficient. Leadership, institutional clarity, and empowered oversight are critical. This is where scientific and public health champions—supported by policy—can have influence. Key leadership roles might include:
Driving feasibility and strategic planning: Ensuring that feasibility studies are not just academic but lead to actionable, financed programs.
Mobilizing stakeholders: Government agencies, NGOs, research institutions, donors, and local communities need to be aligned. Champions who can navigate regulatory bureaucracies, secure funding, promote multisector collaboration, and maintain accountability are essential.
Advocacy and policy development: Promoting policies that favor the development of polyvalent antivenom, regulatory fast-tracking, improved data reporting of snakebite cases, and integration into national health priorities.
Supporting capacity-building: Investing in local manufacturing, regulatory science, clinical trial infrastructure, and product quality monitoring.
Institutional and Leadership Imperatives: A Role for New Champions
To reduce global mortality and morbidity from snakebite, technical solutions alone are insufficient. Leadership, institutional clarity, and empowered oversight are critical. This is where scientific and public health champions, supported by policy, can have influence. Key leadership roles might include:
- Driving feasibility and strategic planning: Ensuring that feasibility studies are not just academic but lead to actionable, financed programs.
- Mobilizing stakeholders: Government agencies, NGOs, research institutions, donors, and local communities need to be aligned. Champions who can navigate regulatory bureaucracies, secure funding, promote multisector collaboration, and maintain accountability are essential.
- Advocacy and policy development: Pushing for policies that favor polyvalent antivenom development, regulatory fast-tracking, better data reporting of snakebite cases, and integration into national health priorities.
- Supporting capacity-building: Investing in local manufacturing, regulatory science, clinical trial infrastructure, and product quality monitoring.
Conclusions and the Path Forward
Snakebite envenoming causes tens of thousands of deaths and many more injuries each year. While monovalent antivenoms still have roles in specific contexts, polyvalent antivenom strategies offer broader, more practical protection in regions with multiple venomous species. Advances in immunology, venom science, and biomanufacturing offer hope for more effective, safer, and more stable antivenoms, reducing dependence on traditional venom milking and improving access.
To make this a reality, however, there must be committed institutional leadership, clear regulatory pathways, sufficient funding, and programs that are locally tailored. Public health initiatives, whether led by governments, global institutions, or scientific champions, must persist in bridging the gap between technical possibilities and lived reality so that every drop of progress contributes to saving lives.
Author’s Note
As someone who works in the global health and life sciences sector, I am committed to advancing solutions in neglected disease spaces. With teams like VTI Life Sciences, I have had the opportunity to support complex biopharma CQV projects and lead research aligned with WHO’s Snakebite Roadmap. Including designing and supporting the development of vaccine facilities around the world, this is a solvable problem.
References
Australian Toxicology Network. (2023). Antivenom usage guidelines and species-specific response in Australia.
Chippaux, J. P. (2017). Snakebite envenomation turns again into a neglected tropical disease!. Journal of Venomous Animals and Toxins including Tropical Diseases, 23, 38. https://doi.org/10.1186/s40409-017-0133-6
Leon, G., et al. (2021). Polyvalent antivenoms: Solution for a multi-snake reality. Toxins, 13(11), 786. https://doi.org/10.3390/toxins13110786
Ratanabanangkoon, K., et al. (2023). Advances in polyvalent antivenom development. Toxicon, 226, 1–10.
Sharma, S. K., Kuch, U., Höde, P., Schmitt, Y., Chappuis, F., & Alirol, E. (2022). Use and effectiveness of polyvalent antivenoms in South Asia. The Lancet Global Health, 10(4), e542–e550. https://doi.org/10.1016/S2214-109X(22)00056-8
World Health Organization. (2023). Snakebite envenoming: A strategy for prevention and control. https://www.who.int/publications/i/item/9789241515641
WHO Regional Office for Africa. (2022). Integrated snakebite envenoming strategy and implementation plan for sub-Saharan Africa. https://www.afro.who.int/
